Haematologie und Onkologie Muenchen-Pasing MVZ GmbH

Munich 8 trials 1 recruiting

8 Registered trials

1 Currently recruiting

Organisation

Haematologie und Onkologie Muenchen-Pasing MVZ GmbH

Location

Munich, Germany

Identifier

ORG-100051117

Address

Baeckerstrasse 4, Pasing-Obermenzing, 81241, Germany

Departments

#2067:Gemeinschaftspraxis Hämato-Onkologie
2604: Onkologie
Haematology/Onkology
Hämatologie - Onkologie
Hämatologie und Onkologie
Innere Medizin

Clinical trials at this site (8)

Search interface

Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia Recruiting

2022-500574-34-00 Waldenström’s Macroglobulinemia 4 2025-03-21
Phase 3 Study to Evaluate Mezigdomide (CC-92480/BMS-986348) in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Mult… Ended

2022-500861-29-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2023-01-12
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With N… Ended

2024-510947-71-00 Chronic Myeloid Leukemia 5 2022-11-21
A phase II, open-label, single arm study to evaluate the efficacy of Luspatercept in Erythropoiesis-stimulating agent naive lower-risk MDS p… Ended

2024-516438-36-00 Patients with very low, low or intermediate risk myelod 4 2022-09-13
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended

2024-511929-60-00 Waldenström’s Macroglobulinemia 4 2021-01-28
Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia Ended

2022-500584-12-00 Waldenström’s Macroglobulinemia 4 2019-09-11
Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended

2023-507669-24-00 Chronic lymphocytic leukemia 5 2019-11-05
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15